Understanding the two faces of the COVID-19 immune response to predict clinical course and define strategies for early and late phase intervention

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.043E+13

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2024
  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)
  • Principal Investigator

    dr S. Nierkens
  • Research Location

    N/A
  • Lead Research Institution

    Universitair Medisch Centrum Utrecht
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Disease models

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The immune system plays a striking dual role in COVID-19. An effective immune response ensures that the virus is attacked and cleared, but if this does not work properly, hyper-activation of the immune system appears to occur, which can lead to serious problems. It is unclear what exactly goes wrong in the immune system in patients with a serious course and how they can best be treated. The use of immune-suppressing medications is one possible strategy. Research and expected outcomes In this study, a collaboration between the UMCU, RIVM and VUmc, a model is developed of the underlying immune response in different phases of COVID by measuring functional cellular defense and circulating protein profiles of patients of different ages and with a variation in disease severity. -19. In addition, predictive biomarkers will be identified and validated that provide insight into optimal timing for specific treatments.